18+ years old Type 1 diabetes and used insulin for at least one year A1c of 7.5% to 10% Administering insulin via multiple daily injections (MDI) or insulin pump user with total daily insulin between 0.3 and 1.5 units per kilogram Body Mass Index (BMI) greater than 18.5 (Calculate your BMI here) Exclusion criteria include: A history of type 2 diabetes Past treatment for type 1 diabetes with any other glucose-lowering drug except basal and bolus insulin during the last three months Severe hypoglycemia or diabetic ketoacidosis in the past three months For a full list of inclusion and exclusion criteria see here
Alternatively, high prolactin levels inhibit GnRH release via interfering with the action of kisspeptin peptide [38], a key hypothalamic regulator of GnRH release leading to decreased luteinizing hormone and subsequently reduce synthesis of testosterone [39, 40, 41]
Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1 and GIP receptor agonist it activates two separate hormonal pathways simultaneously
Mitochondrial compartments are particularly sensitive to these shifts
The primary contraindication for Sermorelin is a personal history of cancer
Thyroid hormone, hypothyroidism, and mast cells: The thyroid is a small gland in the neck that produces hormones that regulate cell metabolism, cardiac output, respiratory rate, alertness, and reproductive health